Indivior (NasdaqGS:INDV): Reassessing Valuation After Positive SUBLOCADE and INDV-2000 Clinical Trial Results

Simply Wall St.2025-12-21

Indivior (NasdaqGS:INDV) just gave investors fresh reasons to revisit the stock, with new clinical data on SUBLOCADE and Phase II results for INDV-2000 underscoring progress in treating high risk ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2593126232?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","is_english":true,"pubTime":"2025-12-21 14:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2593126232","market":"us","top_or_hot":-1,"title":"Indivior (NasdaqGS:INDV): Reassessing Valuation After Positive SUBLOCADE and INDV-2000 Clinical Trial Results","media":"Simply Wall St.","content":"<div>\n<p>Indivior (NasdaqGS:INDV) just gave investors fresh reasons to revisit the stock, with new clinical data on SUBLOCADE and Phase II results for INDV-2000 underscoring progress in treating high risk ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-indv/indivior/news/indivior-nasdaqgsindv-reassessing-valuation-after-positive-s\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Indivior (NasdaqGS:INDV): Reassessing Valuation After Positive SUBLOCADE and INDV-2000 Clinical Trial Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIndivior (NasdaqGS:INDV): Reassessing Valuation After Positive SUBLOCADE and INDV-2000 Clinical Trial Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-21 14:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-indv/indivior/news/indivior-nasdaqgsindv-reassessing-valuation-after-positive-s><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Indivior (NasdaqGS:INDV) just gave investors fresh reasons to revisit the stock, with new clinical data on SUBLOCADE and Phase II results for INDV-2000 underscoring progress in treating high risk ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-indv/indivior/news/indivior-nasdaqgsindv-reassessing-valuation-after-positive-s\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"INDV","symbol_name":"INDIVIOR PLC","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-indv/indivior/news/indivior-nasdaqgsindv-reassessing-valuation-after-positive-s","article_id":"2593126232","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-indv/indivior/news/indivior-nasdaqgsindv-reassessing-valuation-after-positive-s","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2593126232","pubTimestamp":1766297771,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Indivior (NasdaqGS:INDV) just gave investors fresh reasons to revisit the stock, with new clinical data on SUBLOCADE and Phase II results for INDV-2000 underscoring progress in treating high risk opioid use disorder.\nSee our latest analysis for Indivior.\nThose encouraging readouts help explain why Indivior’s 90 day share price return sits at 51.31 percent and its 1 year total shareholder return is 201.97 percent, suggesting momentum is building around the story.\nIf this kind of clinical...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"INDV":"INDIVIOR PLC","BK4007":"制药","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc"},"translate_title":"Indivior（纳斯达克GS：INDV）：SUBLOCADE和INDV-2000临床试验结果呈阳性后重新评估估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INDV":1.5,"DCF":1},"content_text":"Indivior (NasdaqGS:INDV) just gave investors fresh reasons to revisit the stock, with new clinical data on SUBLOCADE and Phase II results for INDV-2000 underscoring progress in treating high risk opioid use disorder. See our latest analysis for Indivior. Those encouraging readouts help explain why Indivior’s 90 day share price return sits at 51.31 percent and its 1 year total shareholder return is 201.97 percent, suggesting momentum is building around the story. If this kind of clinical progress has caught your attention, it could be worth exploring other potential opportunities across healthcare stocks to see how Indivior compares in a broader healthcare context. With shares already up sharply and trading only modestly below analyst targets, the key question now is whether Indivior’s clinical wins still leave upside on the table or if the market has fully priced in its future growth. Price to Earnings of 35.5x, Is it justified? Indivior looks richly priced on a headline basis, with a 35.5x price to earnings ratio at a last close of $35.21, even after its strong recent run. The price to earnings multiple compares what investors pay today with the company’s current earnings, a key yardstick for profitable pharmaceutical and biotech names where cash flows have turned positive. In Indivior’s case, the market appears to be paying up for a sharp inflection in profitability, with earnings expected to grow 39 percent per year, significantly faster than the broader US market. At the same time, our fair value framework suggests a lower fair price to earnings ratio of 27.8x that the market could eventually gravitate toward if expectations cool. That premium becomes clearer against peers, as Indivior trades on 35.5x price to earnings versus the US pharmaceuticals industry average of 19.8x. This underscores how far sentiment has moved and how much future earnings strength investors are already baking in. Explore the SWS fair ratio for Indivior Result: Price-to-Earnings of 35.5x (OVERVALUED) However, downside risks remain if SUBLOCADE growth slows, competitive OUD treatments gain share, or key pipeline assets like INDV-2000 underwhelm in later stage trials. Find out about the key risks to this Indivior narrative. Another View on Indivior's Value While the 35.5x price to earnings ratio makes Indivior look expensive, our DCF model presents a different perspective. It indicates the shares trade around 66.8 percent below an estimated fair value of $106.15 per share, suggesting potential upside if cash flows materialize as expected. Look into how the SWS DCF model arrives at its fair value. INDV Discounted Cash Flow as at Dec 2025Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Indivior for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 914 undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.  Build Your Own Indivior Narrative If you would rather rely on your own analysis and dive into the numbers yourself, you can build a complete narrative in just a few minutes: Do it your way. A great starting point for your Indivior research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision. Ready for your next investing move? Before momentum shifts again, put Simply Wall Street’s Screener to work and line up your next opportunities so you are not scrambling later.  Explore long term wealth-building potential by reviewing steady income candidates through these 12 dividend stocks with yields > 3% and see which payouts might complement your portfolio. Review companies working on innovative technologies by scanning these 24 AI penny stocks and identify those engaged in artificial intelligence. Assess early stage opportunities within these 3634 penny stocks with strong financials and consider how they might fit into a diversified portfolio.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Mobile Infrastructure for Defense and DisasterThe next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.Get the investor briefing before the next round of contractsSponsored On Behalf of CiTechNew: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2593126232","isCrawlerRequest":true}